Comparing two liver cancer treatments for large tumors
Part of Cancer, Digestive system clinical trials.
This trial compares two treatments for people with large liver tumors. One is a liver artery chemotherapy infusion and the other is a chemo-embolization procedure. The study will see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of primary liver cancer (not recurrent).
- You are between 18 and 75 years old.
- Your largest liver tumor is at least 10 cm in size.
- Your cancer is intermediate or advanced, possibly with limited spread to the portal vein or up to 5 small spots outside the liver.
- You must have good liver function (Child-Pugh class A or B) and be in reasonably good health (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
This trial compares two types of tiny beads used in a liver cancer treatment called TACE to see which works better. If you have liver cancer that needs TACE and your liver is still working fairly well, you may be able to join.
This trial tests a combination of treatments—bland transarterial embolization (bTAE), hepatic artery infusion chemotherapy (HAIC), and systemic therapy—for people with large liver cancers that have limited spread. It might be an option if you have a big tumor and your liver is still working well.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial tests a combination of three treatments—a targeted artery procedure, a growth-blocking drug (apatinib), and an immune-boosting drug (camrelizumab)—for people with advanced liver cancer who cannot or do not want surgery. The goal is to shrink tumors and improve survival.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.